What is PharmaLogic?
PharmaLogic Holdings Corp. operates as a global contract development and manufacturing organization (CDMO) with a specialized focus on diagnostic and therapeutic radiopharmaceuticals. Leveraging a robust network of radiopharmacies and manufacturing facilities strategically positioned across North America and Europe, the company excels in the development, production, and distribution of clinical and commercial radiopharmaceutical products. Its services cater to pharmaceutical partners and healthcare providers, facilitating advancements in nuclear medicine and targeted therapies.
How much funding has PharmaLogic raised?
PharmaLogic has raised a total of $2M across 1 funding round:
Debt
$2M
Debt (2020): $2M with participation from PPP
Key Investors in PharmaLogic
PPP
Public-Private Partnership
What's next for PharmaLogic?
The recent major strategic investment signals a new phase of expansion for PharmaLogic. This capital infusion is expected to accelerate the company's growth trajectory, potentially enabling further development of its manufacturing capabilities, expansion into new geographic markets, and the enhancement of its radiopharmaceutical pipeline. The enterprise-level funding context suggests a focus on scaling operations and solidifying its market position as a key player in the specialized CDMO space.
See full PharmaLogic company page
